Market Herald logo

Subscribe

Be the first with the news that moves the market
  • PreveCeutical (PREV) files a PCT (Patent Cooperation Treaty) application for D-amino acid peptides
  • The patent aims to seek protection for certain peptides comprising D-amino acids and their use in treating brain cancer
  • This patent application is made to protect the peptides comprising D-amino acids identified in the BSV research project
  • These peptides have the potential, at least in part, to work as an MMP inhibitor
  • CEO Stephen Van Deventer sat down with Sabrina Cuthbert to discuss the news
  • PreveCeutical is a health sciences company developing innovative options for preventive and curative therapies utilizing organic and natural identical products
  • PreveCeutical Medical (PREV) opened trading at C$0.025

PreveCeutical Medical (PREV) filed a PCT (Patent Cooperation Treaty) application number on November 18.

The company aims to be a leader in the preventive health sciences sector.

For this application, the company entitled the patent, “Peptides and Uses Thereof,” which aims to seek protection for certain peptides comprising D-amino acids and their use in treating brain cancer.

D-Amino is an amino acid comprising d-serine and d-aspartate. Found in the human body, they are the two most commonly studied acids in the human body.

This patent application is made to protect the peptides comprising D-amino acids identified in the BSV research project.

These peptides have the potential, at least in part, to work as an MMP inhibitor.

Stephen Van Deventer has assigned any and all of its rights in the invention and patent to the company.

CEO Stephen Van Deventer sat down with Sabrina Cuthbert to discuss the news.

“This patent will protect the peptides which have the potential for cancer treatments. We are actively seeking partners to work with for these treatments. As my further dedication and commitment to PreveCeutical, I have assigned my inventor and patent rights to the company free of charge.”

Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.

PreveCeutical is a health sciences company developing innovative options for preventive and curative therapies utilizing organic and natural identical products.

PreveCeutical Medical (PREV) opened trading at C$0.025


More From The Market Herald
Sona Nanotech (CSE:SONA) - CEO, David Regan

" Sona Nanotech (CSE:SONA) to acquire cancer therapy developer Siva Therapeutics

Sona Nanotech (SONA) has signed an agreement to acquire Siva Therapeutics Inc.
The Market Herald Video

" Enertopia (CSE:ENRT) provides project update

Enertopia Corporation (ENRT) has provided updates from the West Tonopah Lithium project in Nevada.

" Irwin Naturals (CSE:IWIN) signs LOI to acquire Braxia Scientific (CSE:BRAX)

Irwin Naturals (IWIN) has signed a letter of intent for a business combination with Braxia Scientific Corp. (BRAX).
Reliq Health Technologies - CEO Dr. Lisa Crossley

" Reliq Health Technologies (TSXV:RHT) announces 30 new skilled nursing facility clients and a new contract in Texas

Reliq Health Technologies (RHT) has added 30 new skilled nursing facility clients in Florida and a large allergy and respirology clinic in Texas.